BioCardia Files 8-K Report
Ticker: BCDA · Form: 8-K · Filed: Dec 16, 2025 · CIK: 925741
| Field | Detail |
|---|---|
| Company | Biocardia, Inc. (BCDA) |
| Form Type | 8-K |
| Filed Date | Dec 16, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 B |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, filing
Related Tickers: BCDA
TL;DR
BioCardia filed an 8-K on 12/16/25. Check for updates.
AI Summary
On December 16, 2025, BioCardia, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates BioCardia, Inc. is providing updates or disclosures to the SEC, which could contain important information for investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for disclosures and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- BioCardia, Inc. (company) — Registrant
- December 16, 2025 (date) — Date of earliest event reported
- 320 Soquel Way Sunnyvale, California 94085 (address) — Principal executive offices
FAQ
What specific information is being disclosed under Regulation FD in this 8-K filing?
The provided excerpt does not detail the specific content of the Regulation FD disclosure.
Are there any new financial statements or exhibits attached to this 8-K filing?
The filing indicates that financial statements and exhibits are included, but their specific content is not detailed in the excerpt.
What was the previous name of BioCardia, Inc. and when did the name change occur?
BioCardia, Inc. was formerly known as Tiger X Medical, Inc. after a name change on June 16, 2011.
What is BioCardia, Inc.'s IRS Employer Identification Number (EIN)?
BioCardia, Inc.'s IRS Employer Identification Number is 23-2753988.
In which state was BioCardia, Inc. incorporated?
BioCardia, Inc. was incorporated in Delaware.
Filing Stats: 575 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-16 08:00:11
Key Financial Figures
- $0.001 B — ch registered Common Stock , par value $0.001 BCDA The Nasdaq Capital Market Indicat
Filing Documents
- bcda20251216_8k.htm (8-K) — 23KB
- ex_899241.htm (EX-99.1) — 21KB
- 0001437749-25-037910.txt ( ) — 178KB
- bcda-20251216.xsd (EX-101.SCH) — 3KB
- bcda-20251216_def.xml (EX-101.DEF) — 11KB
- bcda-20251216_lab.xml (EX-101.LAB) — 15KB
- bcda-20251216_pre.xml (EX-101.PRE) — 11KB
- bcda20251216_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 16, 2025, BioCardia, Inc. issued a press release announcing it has completed a third preliminary clinical consultation with Japan's Pharmaceutical and Medical Device Agency (PMDA) on the CardiAMP Cell Therapy intended for the treatment of Heart Failure with Reduced Ejection Fraction (HFrEF). Based on the discussions in this most recent meeting, the PMDA said it will allow BioCardia to advance to a formal clinical consultation. Should the PMDA agree in formal consultation that the available data provides sufficient evidence of safety and efficacy, the Company will be able to file for regulatory approval in Japan. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1 hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that section, nor shall it be deemed to be incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 104 BioCardia, Inc. press release dated December 16, 2025 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOCARDIA, INC. /s/ Peter Altman, Ph.D. Peter Altman, Ph.D. President and Chief Executive Officer Date: December 16, 2025